Donor stem cell therapy delays progression of osteoarthritis
New research by Australian biotechnology company Magellan Stem Cells has demonstrated potential therapeutic benefits of a stem cell therapy for osteoarthritis.
The Phase I/II clinical trial assessed the safety and efficacy of MAG200, Magellan Stem Cells’ off-the-shelf allogeneic (donor) stem cell therapy for osteoarthritis of the knee.
“Our research indicates that Magellan’s off-the-shelf donor stem cell treatment is safe and effective in improving joint function, reducing pain levels and may have the potential to halt the progression of osteoarthritis,” lead researcher Associate Professor Julien Freitag commented.
The demonstrated benefits of Magellan’s MAG200 product included sustained pain improvement of 58% at 12 months of follow-up. Quality of life scores also more than doubled for patients who received stem cell treatment.
“The trial also indicated that Magellan’s cell therapy may delay or prevent the progression of osteoarthritis, with observed improvement in cartilage volume in patients receiving stem cell treatment, while the placebo group showed either no change or their osteoarthritis progressed,” said Associate Professor Freitag.
Long-term clinical follow-up of the single-centre, double-blind, ascending dose, randomised controlled trial has shown that improvements from a single injection of donor stem cells were maintained beyond four years.
No current therapies delay the progression of osteoarthritis, with an increasing number of patients undergoing total knee replacement (TKR) surgery. More than 65,000 TKRs are performed annually in Australia.
“I believe our research results represent a pivotal moment for the management of osteoarthritis and may change the way we practice medicine in the future,” added Associate Professor Freitag. “Cell therapies, including Magellan’s donor stem cell treatment, is a promising and rapidly advancing field with a potential to transform medical management of conditions which currently have limited treatment options.”
Diana Spencer, Senior Digital Content Editor, DDW
